Celcuity, Inc. (NASDAQ:CELC) Given Consensus Rating of "Buy" by Analysts

Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have earned a consensus rating of "Buy" from the six brokerages that are presently covering the company, MarketBeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $28.40.

A number of analysts recently commented on the stock. HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Celcuity in a research note on Monday, May 19th. Needham & Company LLC restated a "buy" rating and set a $29.00 price target on shares of Celcuity in a research note on Monday, June 30th. Finally, Stifel Nicolaus began coverage on shares of Celcuity in a research note on Tuesday, July 1st. They set a "buy" rating and a $30.00 price target on the stock.

Celcuity Trading Up 0.7%

NASDAQ CELC traded up $0.10 during mid-day trading on Tuesday, reaching $13.61. 77,035 shares of the stock were exchanged, compared to its average volume of 240,680. Celcuity has a one year low of $7.57 and a one year high of $19.77. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.61 and a quick ratio of 6.61. The stock has a market cap of $515.22 million, a P/E ratio of -4.49 and a beta of 0.45. The stock has a 50 day simple moving average of $11.65 and a 200-day simple moving average of $11.29.

Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.09. On average, analysts anticipate that Celcuity will post -2.62 EPS for the current year.

Institutional Investors Weigh In On Celcuity

A number of institutional investors have recently made changes to their positions in CELC. Summit Investment Advisors Inc. boosted its stake in shares of Celcuity by 49.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock valued at $45,000 after purchasing an additional 1,132 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Celcuity in the 4th quarter valued at $50,000. Focus Financial Network Inc. purchased a new stake in shares of Celcuity in the 1st quarter valued at $108,000. Perkins Capital Management Inc. purchased a new stake in shares of Celcuity in the 1st quarter valued at $115,000. Finally, GAMMA Investing LLC boosted its position in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after buying an additional 1,225 shares during the period. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.